Japanese drugmaker Takeda signed an agreement March 15 to use contract development and manufacturing company IDT Biologika's facility, which was previously reserved for Takeda’s dengue vaccine candidate, to manufacture Johnson & Johnson's COVID-19 vaccine.
The facility, located in Dessau, Germany, will go back to producing Takeda's dengue vaccine candidate after a three-month period.
Takeda has agreed to help manufacture three different COVID-19 vaccines. The drugmaker has already begun manufacturing Moderna and Novavax vaccines to provide rapid and sustained COVID-19 vaccine access in Japan.
More articles on pharmacy:
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Gilead, Merck co-developing long-acting HIV treatment
© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Read Again https://www.beckershospitalreview.com/pharmacy/takeda-to-manufacture-j-j-s-covid-19-vaccine.htmlBagikan Berita Ini
Related Posts :
San Antonio auto manufacturing booms, promising growth without immediate hiring shifts - WOAI- Politicians Are Showering Manufacturing Companies With Crony Subsidies for 'Job Creation.' It Won't Work. - Reason
- ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property - Yahoo Finance
- Craft Cannery food manufacturing facility in Bergen NY to expand - Democrat & Chronicle
- Study: Manufacturing in U.S. Could Need Up to 3.8 Million Workers - NAM
0 Response to "Takeda to manufacture J&J's COVID-19 vaccine - Becker's Hospital Review"
Post a Comment